Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.69 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.48 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409259 | 1.00 | MAPK14 (0.69) | MAPK14LIMK1LIMK2NUDT1HSP90AA1 | |
| SCHEMBL1617454 | 0.91 | MAPK14 (0.73) | MAPK14LIMK1LIMK2NUDT1HSP90AA1 | |
| SCHEMBL1617118 | 0.88 | MAPK14 (0.66) | MAPK14LIMK1LIMK2NUDT1HSP90AA1 | |
| SCHEMBL4551619 | 0.82 | MAPK14 (1.00) | MAPK14LIMK1LIMK2 | |
| SCHEMBL4405299 | 0.81 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL4406006 | 0.78 | MAPK14 (1.00) | MAPK14LIMK1LIMK2 | |
| SCHEMBL1616715 | 0.78 | MAPK14 (1.00) | MAPK14LIMK1LIMK2HSP90AA1HSP90AB1 | |
| SCHEMBL12716007 | 0.76 | MAPK14 (0.65) | MAPK14LIMK1LIMK2HSP90AA1HSP90AB1 | |
| SCHEMBL1616666 | 0.75 | MAPK14 (0.77) | MAPK14LIMK1LIMK2 | |
| SCHEMBL1617259 | 0.74 | MAPK14 (0.61) | MAPK14LIMK1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848714-B1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20060178388-A1 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178388-A1 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | LIMK1, LIMK2, MAPK1 | MAPK14 83/4885LIMK1 1/4885LIMK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.